CooperCompanies Stock - Analyst consensus and earnings outlook
22.06.2026 - 06:35:33 | ad-hoc-news.de
Edited by ad hoc news Earnings & Calendar Desk. Verified prior to publication on 06/22/2026, 06:32 UTC. Details in the imprint.
CooperCompanies (US21664P1039) combines a global contact lens franchise with a growing fertility and women’s health platform. With no fresh filings or major headlines from investor relations or leading newswires in the past 24 hours, this Monday review centers on the current earnings calendar and market expectations for the stock.
All news and data on CooperCompanies stock
Key figures, recent releases and market data on CooperCompanies stock can be found in the dedicated topic area and on the company’s investor relations pages.
What the calendar shows next
CooperCompanies’ fiscal year typically runs to the end of October, and the group reports quarterly. According to the company’s investor relations materials, management usually releases third-quarter results in late August or early September, followed by full-year numbers later in the fall.
Market data providers currently list the next earnings date as not yet officially scheduled, but positioned for the late summer window based on the historical pattern of prior years. That means the next two to three months will likely bring the next detailed update on revenue, margins and guidance from management.
How earnings expectations stack up
Analyst consensus compiled by major financial portals points to continued growth across CooperVision and CooperSurgical, with expectations for mid-single-digit to low double-digit revenue increases year over year. Estimates also reflect gradual margin improvement as scale benefits and product mix effects build.
On valuation, CooperCompanies stock often trades at a premium earnings multiple versus the broader medical devices peer group, reflecting its focus on recurring consumables such as daily silicone hydrogel lenses and its position in fertility-related procedures. Some analysts see that premium as justified by resilient demand, while others highlight sensitivity to consumer and healthcare spending cycles.
Weekly outlook for investors
For this week, investors are likely to watch broader market risk appetite, bond yields and sector moves in medical technology rather than any company-specific events. CooperCompanies stock tends to react to interest-rate expectations, given the long-duration nature of its growth profile.
Sector news on ophthalmology devices, elective procedures or women’s health volumes can also influence sentiment ahead of results. Against this backdrop, any new commentary from competitors on contact lens pricing, surgical volumes or reimbursement trends may offer indirect signals for CooperCompanies’ upcoming quarters.
The business behind the stock
CooperCompanies generates most of its revenue through CooperVision, a global manufacturer of soft contact lenses across daily, two-week and monthly modalities, with a strong presence in myopia management and toric lenses for astigmatism. The CooperSurgical segment complements this with fertility, women’s health and obstetrics products used by clinics around the world.
Where the stock trades today
The shares of CooperCompanies (US21664P1039) trade on the Nasdaq at ${KURS} as of {KURS_DATUM} UTC.
Key facts on CooperCompanies stock
- Company: CooperCompanies Inc.
- ISIN: US21664P1039
- WKN: 859663
- Ticker: COO
- Venue: Nasdaq
- Price (as of {KURS_DATUM} UTC): ${KURS} USD
- Market cap: {MARKETCAP} USD (as of {KURS_DATUM})
- Sector / Industry: Health Care - Medical Devices
- Index membership: Standard & Poor's 500 index
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
